Prof Christian Willy
Prof Ran Nir-Paz
"I am an Infectious Diseases physician at the Hadassah Hebrew University Medical Center in Jerusalem, Israel. As part of the Infectious Diseases service I support our arthroplasty service which is a referral center from around Israel for the more complicated cases. With that I encounter many patients who have infections which are either chronic or hard to cure using common antibiotics. In order to tackle that we have created an ad-hoc compassionate/ early clinical trial phage treatment center with the Hazan Lab@huji. We already successfully treated one patient and few more are on the way."
Kristin Wannerberger
Kristin holds a Ph.D. in Biophysical Technology from Lund University, Sweden and a M.Sc. Chem. Eng. - Food and Dairy Technology. Kristin has more than 20 years of experience of Pharmaceutical Industry working with development of drugs covering various therapeutical areas and several administration forms. She has had various positions based in Sweden, Denmark and Switzerland and currently holds a position as Director Alliance Management R&D, based in Switzerland. She is directing several alliances in the field of the human microbiota/microbiome.
Dr Ronen Hazan
Dr Steven Hagens
After 22 years working with phages both in academia and industry my role is to act as interface between Micreos Food Safety B.V. and various stakeholders such as regulatory authorities in various countries, large customers in the food industry, academic partners with whom we collaborate as well as ensuring our intellectual property portfolio is well stocked. In addition I guide and sometimes direct new product development within our own research team.
Dr Miguel Baretto-Sanz
Our company Phages4A (Phages For All) has developed a technology based on artificial intelligence, able to predict in an in-silico way (via computer simulation) the phages that can specifically infect and kill a bacteria. Our technology harnesses the genome of phages and bacteria and relies on bacterial-phage interaction databases to train artificial intelligence algorithms. The models thus developed make it possible to select the phages that can specifically infect and kill a given bacteria. Our predictions help to create custom bacteriophage cocktails to treat patients with bacterial infections.
More specifically we aim to:
- Help companies working on phage therapy to speed their processes to identify host range
- Provide to hospitals and clinics with software tools to accelerate the treatment of patients suffering of diseases related antibiotic-resistant bacteria.
- Bring our products and services to other industries including but not limited to food safety, aquaculture, veterinary, and agriculture where bacteria resistant to antibiotics is an important issue.
Dr Gregory Resch
Dr Aleksandra Petrovic Fabijan
Dr Pieter-Jan Ceyssens
Eric Pelfrene
I am employed at the European Medicines Agency (EMA), with responsibilities mainly focused on regulatory guidance pertaining new antibacterial products and medicines for use against WHO target infections, such as malaria. At EMA we are looking at the lifecycle of each product, through registration and post-authorisation phase, ensuring safe and effective medicines with certified quality to be available for patients throughout the European Union. The Agency also plays a role in supporting research and innovation in the pharmaceutical sector and promotes innovation and development of new medicines by European micro- small- and medium-sized-enterprises.